Action Strategic Minerals Europ... - SNTA

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,005

Prix Achat

0,005

Prix Vente

0,005

Volume échangé

0,00 Fourchette du Jour 0,00

0,005 Plage de 52 semaines 0,03

Clôture Veille

0,005

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeutics PR Newswire NEW...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ: SNTA) announced today that the annual meeting of stockholders to approve, among other things...

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by...

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics PR Newswire NEW YORK, May 27, 2016 NEW YORK, May...

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

– Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies – – Paul A. Friedman, M.D. Named Chairman and Chief...

Synta Reports Third Quarter 2015 Financial Results

Announces Reduction in Force, Appointment of Scott Morenstein to Board of Directors Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today...

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Company to Host Conference Call on Wednesday, October 21 at 8:00 AM ET Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the...

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the formation of an Expert Oncology Panel to provide guidance on research and...

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Alan C. Rigby, Ph.D., as the Company’s Senior Vice President...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0.005	0.01	0.005	91250	0.00570582	CS
52	-0.02	-80	0.025	0.03	0.005	169445	0.01414065	CS
156	-0.37	-98.6666666667	0.375	0.435	0.005	65652	0.05297928	CS
260	-0.245	-98	0.25	0.53	0.005	64790	0.09737473	CS

SNTA - Frequently Asked Questions (FAQ)

What is the current Strategic Minerals Europ... share price?

The current share price of Strategic Minerals Europ... is $ 0,005

What is the 1 year trading range for Strategic Minerals Europ... share price?

Strategic Minerals Europ... has traded in the range of $ 0,005 to $ 0,03 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
GRAMGold Flora Corporation	$ 0,05 (25,00%)	10k
SUNNSolarBank Corporation	$ 5,55 (6,73%)	13,94k
CBSTCannabist Company Holdings Inc	$ 0,08 (6,67%)	80,05k
KNRKontrol Technologies Corp	$ 0,17 (6,25%)	6k
JPEGPioneer Media Holdings Inc	$ 0,27 (5,88%)	182k
ZEFIZefiro Methane Corp	$ 0,43 (-4,44%)	1 000
BLKBlackrock CDR	$ 24,06 (-3,91%)	19,47k
NOWSServicenow CDR	$ 21,70 (-3,77%)	28,79k
DEFIValour Inc	$ 3,30 (-3,51%)	990,38k
BTQBTQ Technologies Corp	$ 2,61 (-2,97%)	248,99k
DEFIValour Inc	$ 3,30 (-3,51%)	990,38k
ALGOLight AI Inc	0,62 (3,33%)	412,73k
BTQBTQ Technologies Corp	$ 2,61 (-2,97%)	248,99k
LITSLithos Energy Ltd	$ 0,025 (0,00%)	236,85k
JPEGPioneer Media Holdings Inc	$ 0,27 (5,88%)	182k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Strategic Minerals Europe Corp WTS (SNTA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNTA Dernières nouvelles

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Synta Reports Third Quarter 2015 Financial Results

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

SNTA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Strategic Minerals Europe Corp WTS (SNTA) Cours

Strategic Minerals Europe Corp WTS (SNTA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

SNTA Dernières nouvelles

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...

Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals

Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Synta Reports Third Quarter 2015 Financial Results

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Synta Pharmaceuticals Announces Formation of Expert Oncology Panel

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

SNTA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités